Language:
  
[Sign in] [Register]   

EIAab logo

Index > Protein center > LRRK2(Gene name) > Human
  • Add your favorite
  • LRRK2 (Gene name),
  • Leucine-rich repeat serine/threonine-protein kinase 2 (Protein name ),  LRRK2_HUMAN from NCBI database.
  • top
  • Come back to page head.
  • |
  • General Annotation
  • |
  • Antigen Annotation
  • |
  • 3D
  • |
  • Predicted Eptitope
  • |
  • Vaild Sequence
  • |
  • Related Databases
  • |
  • Feedback
  • Gene name:
    LRRK2(PARK8);
    Protein name:
    Leucine-rich repeat serine/threonine-protein kinase 2;
    Alternative:
    Dardarin;
    Organism:
    Human (Homo sapiens). 
    General Annotation
    Sub Unit:
    Interacts with PARK2.
    Function:
    Probable protein kinase whose role is not yet known. May play a role in the phosphorylation of proteins central to Parkinson disease. May also have GTPase activity.
    Subcellular Location:
    Cytoplasm Membrane Peripheral membrane protein Localized in the cytoplasm and associated with cellular membrane structures. Associates with the mitochondrial outer membrane.
    Protein Attributes:
    Sequence length:
    2527
    Sequence:
    50:
    MASGSCQGCE | EDEETLKKLI | VRLNNVQEGK | QIETLVQILE | DLLVFTYSER | 
    100:
    ASKLFQGKNI | HVPLLIVLDS | YMRVASVQQV | GWSLLCKLIE | VCPGTMQSLM | 
    150:
    GPQDVGNDWE | VLGVHQLILK | MLTVHNASVN | LSVIGLKTLD | LLLTSGKITL | 
    200:
    LILDEESDIF | MLIFDAMHSF | PANDEVQKLG | CKALHVLFER | VSEEQLTEFV | 
    250:
    ENKDYMILLS | ALTNFKDEEE | IVLHVLHCLH | SLAIPCNNVE | VLMSGNVRCY | 
    300:
    NIVVEAMKAF | PMSERIQEVS | CCLLHRLTLG | NFFNILVLNE | VHEFVVKAVQ | 
    350:
    QYPENAALQI | SALSCLALLT | ETIFLNQDLE | EKNENQENDD | EGEEDKLFWL | 
    400:
    EACYKALTWH | RKNKHVQEAA | CWALNNLLMY | QNSLHEKIGD | EDGHFPAHRE | 
    450:
    VMLSMLMHSS | SKEVFQASAN | ALSTLLEQNV | NFRKILLSKG | IHLNVLELMQ | 
    500:
    KHIHSPEVAE | SGCKMLNHLF | EGSNTSLDIM | AAVVPKILTV | MKRHETSLPV | 
    550:
    QLEALRAILH | FIVPGMPEES | REDTEFHHKL | NMVKKQCFKN | DIHKLVLAAL | 
    600:
    NRFIGNPGIQ | KCGLKVISSI | VHFPDALEML | SLEGAMDSVL | HTLQMYPDDQ | 
    650:
    EIQCLGLSLI | GYLITKKNVF | IGTGHLLAKI | LVSSLYRFKD | VAEIQTKGFQ | 
    700:
    TILAILKLSA | SFSKLLVHHS | FDLVIFHQMS | SNIMEQKDQQ | FLNLCCKCFA | 
    750:
    KVAMDDYLKN | VMLERACDQN | NSIMVECLLL | LGADANQAKE | GSSLICQVCE | 
    800:
    KESSPKLVEL | LLNSGSREQD | VRKALTISIG | KGDSQIISLL | LRRLALDVAN | 
    850:
    NSICLGGFCI | GKVEPSWLGP | LFPDKTSNLR | KQTNIASTLA | RMVIRYQMKS | 
    900:
    AVEEGTASGS | DGNFSEDVLS | KFDEWTFIPD | SSMDSVFAQS | DDLDSEGSEG | 
    950:
    SFLVKKKSNS | ISVGEFYRDA | VLQRCSPNLQ | RHSNSLGPIF | DHEDLLKRKR | 
    1000:
    KILSSDDSLR | SSKLQSHMRH | SDSISSLASE | REYITSLDLS | ANELRDIDAL | 
    1050:
    SQKCCISVHL | EHLEKLELHQ | NALTSFPQQL | CETLKSLTHL | DLHSNKFTSF | 
    1100:
    PSYLLKMSCI | ANLDVSRNDI | GPSVVLDPTV | KCPTLKQFNL | SYNQLSFVPE | 
    1150:
    NLTDVVEKLE | QLILEGNKIS | GICSPLRLKE | LKILNLSKNH | ISSLSENFLE | 
    1200:
    ACPKVESFSA | RMNFLAAMPF | LPPSMTILKL | SQNKFSCIPE | AILNLPHLRS | 
    1250:
    LDMSSNDIQY | LPGPAHWKSL | NLRELLFSHN | QISILDLSEK | AYLWSRVEKL | 
    1300:
    HLSHNKLKEI | PPEIGCLENL | TSLDVSYNLE | LRSFPNEMGK | LSKIWDLPLD | 
    1350:
    ELHLNFDFKH | IGCKAKDIIR | FLQQRLKKAV | PYNRMKLMIV | GNTGSGKTTL | 
    1400:
    LQQLMKTKKS | DLGMQSATVG | IDVKDWPIQI | RDKRKRDLVL | NVWDFAGREE | 
    1450:
    FYSTHPHFMT | QRALYLAVYD | LSKGQAEVDA | MKPWLFNIKA | RASSSPVILV | 
    1500:
    GTHLDVSDEK | QRKACMSKIT | KELLNKRGFP | AIRDYHFVNA | TEESDALAKL | 
    1550:
    RKTIINESLN | FKIRDQLVVG | QLIPDCYVEL | EKIILSERKN | VPIEFPVIDR | 
    1600:
    KRLLQLVREN | QLQLDENELP | HAVHFLNESG | VLLHFQDPAL | QLSDLYFVEP | 
    1650:
    KWLCKIMAQI | LTVKVEGCPK | HPKGIISRRD | VEKFLSKKRK | FPKNYMSQYF | 
    1700:
    KLLEKFQIAL | PIGEEYLLVP | SSLSDHRPVI | ELPHCENSEI | IIRLYEMPYF | 
    1750:
    PMGFWSRLIN | RLLEISPYML | SGRERALRPN | RMYWRQGIYL | NWSPEAYCLV | 
    1800:
    GSEVLDNHPE | SFLKITVPSC | RKGCILLGQV | VDHIDSLMEE | WFPGLLEIDI | 
    1850:
    CGEGETLLKK | WALYSFNDGE | EHQKILLDDL | MKKAEEGDLL | VNPDQPRLTI | 
    1900:
    PISQIAPDLI | LADLPRNIML | NNDELEFEQA | PEFLLGDGSF | GSVYRAAYEG | 
    1950:
    EEVAVKIFNK | HTSLRLLRQE | LVVLCHLHHP | SLISLLAAGI | RPRMLVMELA | 
    2000:
    SKGSLDRLLQ | QDKASLTRTL | QHRIALHVAD | GLRYLHSAMI | IYRDLKPHNV | 
    2050:
    LLFTLYPNAA | IIAKIADYGI | AQYCCRMGIK | TSEGTPGFRA | PEVARGNVIY | 
    2100:
    NQQADVYSFG | LLLYDILTTG | GRIVEGLKFP | NEFDELEIQG | KLPDPVKEYG | 
    2150:
    CAPWPMVEKL | IKQCLKENPQ | ERPTSAQVFD | ILNSAELVCL | TRRILLPKNV | 
    2200:
    IVECMVATHH | NSRNASIWLG | CGHTDRGQLS | FLDLNTEGYT | SEEVADSRIL | 
    2250:
    CLALVHLPVE | KESWIVSGTQ | SGTLLVINTE | DGKKRHTLEK | MTDSVTCLYC | 
    2300:
    NSFSKQSKQK | NFLLVGTADG | KLAIFEDKTV | KLKGAAPLKI | LNIGNVSTPL | 
    2350:
    MCLSESTNST | ERNVMWGGCG | TKIFSFSNDF | TIQKLIETRT | SQLFSYAAFS | 
    2400:
    DSNIITVVVD | TALYIAKQNS | PVVEVWDKKT | EKLCGLIDCV | HFLREVMVKE | 
    2450:
    NKESKHKMSY | SGRVKTLCLQ | KNTALWIGTG | GGHILLLDLS | TRRLIRVIYN | 
    2500:
    FCNSVRVMMT | AQLGSLKNVM | LVLGYNRKNT | EGTQKQKEIQ | SCLTVWDINL | 
    2527:
    PHEVQNLEKH | IEVRKELAEK | MRRTSVE
    3D Structure:
    N/A
    Predicted Eptitope:
    Please Sign in.
    EIAab Sequence  Vaild Sequence:
    Please Sign in.
    Related Databases
    UniGene:
    MIM:
    String:
    Pfam:
    SMR:
    Uniprot:
     
    FOR
    ELISA Kit for Human Leucine-rich repeat serine/threonine-protein kinase 2
    Cat.:
    E1515h
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    ELISA Kit for Human Leucine-rich repeat serine/threonine-protein kinase 2
    Cat.:
    E1515m
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    CLIA Kit for Human Leucine-rich repeat serine/threonine-protein kinase 2
    Cat.:
    U1515h
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Range:
    Please sign in first.
    CLIA Kit for Human Leucine-rich repeat serine/threonine-protein kinase 2
    Cat.:
    U1515m
    Price:
    Please sign in first.
    MSDS:
    Please sign in first.
    Packing:
    96T
    Polyclonal Antibody for Human Leucine-rich repeat serine/threonine-protein kinase 2
    Cat.:
    P1515Rb-m
    Price:
    Please sign in first.
    Packing:
    40ug/0.2ml
    Polyclonal Antibody for Human Leucine-rich repeat serine/threonine-protein kinase 2
    Cat.:
    P1515Rb-h
    Price:
    Please sign in first.
    Packing:
    40ug/0.2ml
    Monoclonal Antibody for Human Leucine-rich repeat serine/threonine-protein kinase 2
    Monoclonal Antibody for Human Leucine-rich repeat serine/threonine-protein kinase 2
    Protein for Human Leucine-rich repeat serine/threonine-protein kinase 2
    Protein for Human Leucine-rich repeat serine/threonine-protein kinase 2

    R&D Technical Data
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Precision
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Recovery
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    Linearity
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    For more information, please refer to the manual,Or contact our technical support: tech@eiaab.com.
    References
    1. 1.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [MRNA];TISSUE SPECIFICITY;VARIANTS PARK8 VAL-1122; CYS-1441; CYS-1699 AND THR-2020
      tissue: Brain.
    2. 2.
      "The finished DNA sequence of human chromosome 12."
      Scherer S.E. , Muzny D.M. , Buhay C.J. , Chen R. , Cree A. , Ding Y. , Dugan-Rocha S. , Gill R. , Gunaratne P. , Harris R.A. , Hawes A.C. , Hernandez J. , Hodgson A.V. , Hume J. , Jackson A. , Khan Z.M. , Kovar-Smith C. , Lewis L.R. , more...
      Nature440:346-351(2006) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA]
    3. 3.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 2128-2527
      tissue: Testis.
    4. 4.
      "PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation."
      Adams J.R. , van Netten H. , Schulzer M. , Mak E. , McKenzie J. , Strongosky A. , Sossi V. , Ruth T.J. , Lee C.S. , Farrer M. , Gasser T. , Uitti R.J. , Calne D.B. , Wszolek Z.K. , Stoessl A.J.
      Brain128:2777-2785(2005) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: DISEASE
    5. 5.
      "The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity."
      Gloeckner C.J. , Kinkl N. , Schumacher A. , Braun R.J. , O'Neill E. , Meitinger T. , Kolch W. , Prokisch H. , Ueffing M.
      Hum. Mol. Genet.15:223-232(2006) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: SUBCELLULAR LOCATION;CHARACTERIZATION OF VARIANT PARK8 THR-2020
    6. 6.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: DISEASE
    7. 7.
      "Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity."
      West A.B. , Moore D.J. , Biskup S. , Bugayenko A. , Smith W.W. , Ross C.A. , Dawson V.L. , Dawson T.M.
      Proc. Natl. Acad. Sci. U.S.A.102:16842-16847(2005) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: SUBCELLULAR LOCATION;CHARACTERIZATION OF VARIANTS PARK8 CYS-1441 AND SER-2019
    8. 8.
      "Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin and mutant LRRK2 induces neuronal degeneration."
      Smith W.W. , Pei Z. , Jiang H. , Moore D.J. , Liang Y. , West A.B. , Dawson V.L. , Dawson T.M. , Ross C.A.
      Proc. Natl. Acad. Sci. U.S.A.102:18676-18681(2005) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: SUBCELLULAR LOCATION;INTERACTION WITH PARK2;POSSIBLE FUNCTION
    9. 9.
      "LRRK2 expression linked to dopamine-innervated areas."
      Galter D. , Westerlund M. , Carmine A. , Lindqvist E. , Sydow O. , Olson L.
      Ann. Neurol.59:714-719(2006) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: TISSUE SPECIFICITY
    10. 10.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: SUBCELLULAR LOCATION;TISSUE SPECIFICITY
    11. 11.
      "The familial Parkinsonism gene LRRK2 regulates neurite process morphology."
      MacLeod D. , Dowman J. , Hammond R. , Leete T. , Inoue K. , Abeliovich A.
      Neuron52:587-593(2006) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION;CHARACTERIZATION OF VARIANTS PARK8 GLY-1441; CYS-1699; SER-2019 AND THR-2020;VARIANT MET-1906
    12. 12.
      "Signal transduction protein array analysis links LRRK2 to Ste20 kinases and PKC zeta that modulate neuronal plasticity."
      Zach S. , Felk S. , Gillardon F.
      PLoS ONE5:E13191-E13191(2010) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION
    13. 13.
      "Mutations in LRRK2 increase phosphorylation of peroxiredoxin 3 exacerbating oxidative stress-induced neuronal death."
      Angeles D.C. , Gan B.H. , Onstead L. , Zhao Y. , Lim K.L. , Dachsel J. , Melrose H. , Farrer M. , Wszolek Z.K. , Dickson D.W. , Tan E.K.
      Hum. Mutat.32:1390-1397(2011) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION;SUBCELLULAR LOCATION;INTERACTION WITH PRDX3;CHARACTERIZATION OF VARIANT PARK8 SER-2019
    14. 14.
      "Leucine-rich repeat kinase 2 regulates autophagy through a calcium-dependent pathway involving NAADP."
      Gomez-Suaga P. , Luzon-Toro B. , Churamani D. , Zhang L. , Bloor-Young D. , Patel S. , Woodman P.G. , Churchill G.C. , Hilfiker S.
      Hum. Mol. Genet.21:511-525(2012) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION;INTERACTION WITH TPCN2
    15. 15.
      "Biochemical characterization of highly purified leucine-rich repeat kinases 1 and 2 demonstrates formation of homodimers."
      Civiero L. , Vancraenenbroeck R. , Belluzzi E. , Beilina A. , Lobbestael E. , Reyniers L. , Gao F. , Micetic I. , De Maeyer M. , Bubacco L. , Baekelandt V. , Cookson M.R. , Greggio E. , Taymans J.M.
      PLoS ONE7:E43472-E43472(2012) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: SUBUNIT;AUTOPHOSPHORYLATION
    16. 16.
      "RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk."
      MacLeod D.A. , Rhinn H. , Kuwahara T. , Zolin A. , Di Paolo G. , McCabe B.D. , MacCabe B.D. , Marder K.S. , Honig L.S. , Clark L.N. , Small S.A. , Abeliovich A.
      Neuron77:425-439(2013) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: FUNCTION IN RETROGRADE TRANSPORT;INTERACTION WITH RAB29 AND VPS35;SUBCELLULAR LOCATION;CHARACTERIZATION OF VARIANT PARK8 SER-2019;CHARACTERIZATION OF VARIANT MET-1906
    17. 17.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS PARK8 GLY-1441 AND CYS-1699;TISSUE SPECIFICITY
    18. 18.
      "Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations."
      Kachergus J.M. , Mata I.F. , Hulihan M. , Taylor J.P. , Lincoln S. , Aasly J.O. , Gibson J.M. , Ross O.A. , Lynch T. , Wiley J. , Payami H. , Nutt J. , Maraganore D.M. , Czyzewski K. , Styczynska M. , Wszolek Z.K. , Farrer M.J. , Toft M.
      Am. J. Hum. Genet.76:672-680(2005) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT PARK8 SER-2019
    19. 19.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT PARK8 SER-2019
    20. 20.
      "Clinical features of LRRK2-associated Parkinson's disease in central Norway."
      Aasly J.O. , Toft M. , Fernandez-Mata I. , Kachergus J.M. , Hulihan M. , White L.R. , Farrer M.J.
      Ann. Neurol.57:762-765(2005) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT PARK8/PD SER-2019
    21. 21.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT PARK8 SER-2019
    22. 22.
      "An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family."
      Funayama M. , Hasegawa K. , Ohta E. , Kawashima N. , Komiyama M. , Kowa H. , Tsuji S. , Obata F.
      Ann. Neurol.57:918-921(2005) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT PARK8 THR-2020
    23. 23.
      "Genetic and clinical identification of Parkinson's disease patients with LRRK2 G2019S mutation."
      Deng H. , Le W. , Guo Y. , Hunter C.B. , Xie W. , Jankovic J.
      Ann. Neurol.57:933-934(2005) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT PARK8 SER-2019
    24. 24.
      "Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease."
      Berg D. , Schweitzer K. , Leitner P. , Zimprich A. , Lichtner P. , Belcredi P. , Bruessel T. , Schulte C. , Maass S. , Naegele T.
      Brain128:3000-3011(2005) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS PARK8 MET-793; ARG-930; CYS-1096 THR-1228; SER-2019 AND THR-2020;VARIANT LYS-551
    25. 25.
      "Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data."
      Khan N.L. , Jain S. , Lynch J.M. , Pavese N. , Abou-Sleiman P.M. , Holton J.L. , Healy D.G. , Gilks W.P. , Sweeney M.G. , Ganguly M. , Gibbons V. , Gandhi S. , Vaughan J. , Eunson L.H. , Katzenschlager R. , Gayton J. , Lennox G. , Revesz T. , more...
      Brain128:2786-2796(2005) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS PARK8 CYS-1699; HIS-1941; SER-2019 AND ILE-2356
    26. 26.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS PARK8 VAL-1371; CYS-1441 AND SER-2019
    27. 27.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT PARK8 SER-2019
    28. 28.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT PARK8 SER-2019
    29. 29.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT PARK8 SER-2019
    30. 30.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT PARK8 SER-2019
    31. 31.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT PARK8 SER-2019
    32. 32.
      "Escaping Parkinson's disease: a neurologically healthy octogenarian with the LRRK2 G2019S mutation."
      Kay D.M. , Kramer P. , Higgins D.S. , Zabetian C.P. , Payami H.
      Mov. Disord.20:1077-1078(2005) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT SER-2019
    33. 33.
      "Parkinson's disease and LRRK2: frequency of a common mutation in U.S. movement disorder clinics."
      Kay D.M. , Zabetian C.P. , Factor S.A. , Nutt J.G. , Samii A. , Griffith A. , Bird T.D. , Kramer P. , Higgins D.S. , Payami H.
      Mov. Disord.21:519-523(2006) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT PARK8 SER-2019
    34. 34.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS PARK8 CYS-1441; GLY-1441; HIS-1441; GLN-1514; SER-1542; GLU-1598; CYS-1699; THR-1869; THR-2012; SER-2019; THR-2020 AND ARG-2385;VARIANTS PRO-119; LYS-551; VAL-723; MET-793; VAL-1122; ALA-1262; HIS-1398; PRO-1628; THR-1646; THR-1647; ASP-2081; LEU-2119; ILE-2261 AND THR-2397
    35. 35.
      "LRRK2 gene in Parkinson disease: mutation analysis and case control association study."
      Paisan-Ruiz C. , Lang A.E. , Kawarai T. , Sato C. , Salehi-Rad S. , Fisman G.K. , Al-Khairallah T. , St George-Hyslop P.H. , Singleton A. , Rogaeva E.
      Neurology65:696-700(2005) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS PARK8 VAL-1371 AND SER-2019;VARIANTS HIS-1398 AND THR-2397
    36. 36.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT PARK8 GLN-1067
    37. 37.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS PARK8 MET-793; THR-1869 AND SER-2019
    38. 38.
      "A clinic-based study of the LRRK2 gene in Parkinson disease yields new mutations."
      Zabetian C.P. , Samii A. , Mosley A.D. , Roberts J.W. , Leis B.C. , Yearout D. , Raskind W.H. , Griffith A.
      Neurology65:741-744(2005) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS PARK8 CYS-1441; HIS-1441 AND SER-2019
    39. 39.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT PARK8 GLY-1441
    40. 40.
      "LRRK2 G2019S is a common mutation in Spanish patients with late-onset Parkinson's disease."
      Infante J. , Rodriguez E. , Combarros O. , Mateo I. , Fontalba A. , Pascual J. , Oterino A. , Polo J.M. , Leno C. , Berciano J.
      Neurosci. Lett.395:224-226(2006) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT PARK8 SER-2019
    41. 41.
      "Clinical traits of LRRK2-associated Parkinson's disease in Ireland: a link between familial and idiopathic PD."
      Gosal D. , Ross O.A. , Wiley J. , Irvine G.B. , Johnston J.A. , Toft M. , Mata I.F. , Kachergus J. , Hulihan M. , Taylor J.P. , Lincoln S.J. , Farrer M.J. , Lynch T. , Mark Gibson J.
      Parkinsonism Relat. Disord.11:349-352(2005) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT PARK8 SER-2019
    42. 42.
      "LRRK2 mutations in Spanish patients with Parkinson disease: frequency, clinical features, and incomplete penetrance."
      Gaig C. , Ezquerra M. , Marti M.J. , Munoz E. , Valldeoriola F. , Tolosa E.
      Arch. Neurol.63:377-382(2006) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS PARK8 CYS-1441; GLY-1441 AND SER-2019
    43. 43.
      "The LRRK2 Gly2385Arg variant is associated with Parkinson's disease: genetic and functional evidence."
      Tan E.K. , Zhao Y. , Skipper L. , Tan M.G. , Di Fonzo A. , Sun L. , Fook-Chong S. , Tang S. , Chua E. , Yuen Y. , Tan L. , Pavanni R. , Wong M.C. , Kolatkar P. , Lu C.S. , Bonifati V. , Liu J.J.
      Hum. Genet.120:857-863(2007) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: CHARACTERIZATION OF VARIANT ARG-2385;ASSOCIATION WITH PARKINSON DISEASE
    44. 44.
      "Patterns of somatic mutation in human cancer genomes."
      Greenman C. , Stephens P. , Smith R. , Dalgliesh G.L. , Hunter C. , Bignell G. , Davies H. , Teague J. , Butler A. , Stevens C. , Edkins S. , O'Meara S. , Vastrik I. , Schmidt E.E. , Avis T. , Barthorpe S. , Bhamra G. , Buck G. , more...
      Nature446:153-158(2007) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS [LARGE SCALE ANALYSIS] PRO-119; VAL-419; LYS-551; VAL-723; HIS-1398; GLN-1514; SER-1542; GLN-1550 AND PRO-1723
    45. 45.
      "Comprehensive analysis of LRRK2 in publicly available Parkinson's disease cases and neurologically normal controls."
      Paisan-Ruiz C. , Nath P. , Washecka N. , Gibbs J.R. , Singleton A.B.
      Hum. Mutat.29:485-490(2008) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS PARK8 VAL-712; LEU-1728; HIS-1728; SER-2019; MET-2141; HIS-2143 AND HIS-2466;VARIANTS SER-228; VAL-716; GLU-871; PHE-1870 AND LYS-2395
    46. 46.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT ILE-1359
    47. 47.
      "Genetic characteristics of leucine-rich repeat kinase 2 (LRRK2) associated Parkinson's disease."
      Bardien S. , Lesage S. , Brice A. , Carr J.
      Parkinsonism Relat. Disord.17:501-508(2011) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: ASSOCIATION OF VARIANTS PRO-1628 AND ARG-2385 WITH PARKINSON DISEASE
    48. 48.
      "Deep sequencing of the LRRK2 gene in 14,002 individuals reveals evidence of purifying selection and independent origin of the p.Arg1628Pro mutation in Europe."
      Rubio J.P. , Topp S. , Warren L. , St Jean P.L. , Wegmann D. , Kessner D. , Novembre J. , Shen J. , Fraser D. , Aponte J. , Nangle K. , Cardon L.R. , Ehm M.G. , Chissoe S.L. , Whittaker J.C. , Nelson M.R. , Mooser V.E.
      Hum. Mutat.33:1087-1098(2012) [PubMed] [Europe PMC] [Abstract]
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANTS LYS-551; VAL-723; HIS-1398; GLN-1514; SER-1542; PRO-1628; THR-1646; THR-1647; ASP-2081 AND THR-2397
    49. 49.
      [15/1/25 17:38] Upload to ab completed in less than a minute: 1 file transferred (13.4 Kb/s) Cited for: VARIANT PARK8 SER-2019
    Product Feedback Wall
    Hot Genes
    Atf2 ASPRO ACE ALCAM C19orf80 Trap1a KSR2 Gdf5
    Top Searches
    Ubiquitin-protein ligase Ubiquitin ELISA metalloproteinase Tumor necrosis Asprosin TRAP1A Alpha
    Why choose EIAAB
    Our products have been quoted by many publications in famous journals such as Cell; Cell Metabolism; Hepatology; Biomaterials.more
    Further Information
    About us Protein center Bank account Distributors Terms & Conditions Career eiaab.cn

    Copyright & copy www.eiaab.com2006-2016 All Rights Reserved    EIAab         Email:eiaab@eiaab.com

    Twitter